公开(公告)号：US20170065698A1

公开(公告)日：2017-03-09

申请号：US15354102

申请日：2016-11-17

Applicant: STICHTING KATHOLIEKE UNIVERSITEIT/RADBOUD UNIVERSITY NIJMEGEN MEDICAL CENTRE

Inventor： Hester Jeanette Bootsma ,  Pieter Jan Burghout ,  Peter Wilhelmus Maria Hermans ,  Johanna Jacoba Elisabeth Bijlsma ,  Oscar Paul Kuipers ,  Tomas Gerrit Kloosterman

IPC: A61K39/09 ,  A61K47/22 ,  A61K9/107 ,  A61K9/00

CPC classification number: A61K39/092 ,  A61K9/0019 ,  A61K9/107 ,  A61K39/09 ,  A61K47/22 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/55594

Abstract: The present invention provides proteins/genes, which are essential for survival, and consequently, for virulence of Streptococcus pneumoniae in vivo, and thus are ideal vaccine candidates for a vaccine preparation against pneumococcal infection. Further, also antibodies against said protein(s) are included in the invention.

Abstract translation: 本发明提供蛋白质/基因，其对于存活是必需的，因此提供了肺炎链球菌在体内的毒力，因此是针对肺炎球菌感染的疫苗制剂的理想疫苗候选物。 此外，本发明还包括针对所述蛋白质的抗体。

公开(公告)号：US20240166683A1

公开(公告)日：2024-05-23

申请号：US18503951

申请日：2023-11-07

Applicant: UNIVERSITY OF SOUTHERN CALIFORNIA ,  RADBOUD UNIVERSITY NIJMEGEN

Inventor： Zhipeng LU ,  Willem A. VELEMA ,  Ryan VAN DAMME

IPC: C07H21/02 ,  C12N15/11

CPC classification number: C07H21/02 ,  C12N15/111 ,  C12N2310/351 ,  C12N2320/51

Abstract: Reversible Spatial 2′ Hydroxyl Acylation Reversible Crosslinking (SHARC) agents and methods of using the same to determine spatial distance between nucleotides in a ribonucleic acid (RNA) molecule.

公开(公告)号：US20150105516A1

公开(公告)日：2015-04-16

申请号：US14577038

申请日：2014-12-19

Applicant: Stichting Katholieke Universiteit Meer in Het Bijzonder Radboud University Nijmegen

Inventor： Alan Edward Rowan ,  Roeland Johannes Maria Nolte ,  Jeroen Johannes Lambertus Maria Cornelissen ,  Heather Joy Kitto ,  Erik Schwartz ,  Matthieu Koepf

IPC: C08G69/40 ,  C09D177/04 ,  C08L77/04

CPC classification number: C08G69/40 ,  C08G65/33348 ,  C08L77/04 ,  C08L2201/54 ,  C09D177/04

Abstract: The present invention relates to a process for the preparation of oligo(alkylene glycol)-functionalized polyisocyanopeptides comprising the steps of functionalizing an isocyanopeptide with oligo-(alkylene glycol) side chains and subsequently polymerizing the oligo-alkylene glycol-functionalized isocyanopeptides. Several isocyanopeptides may be functionalized with various linear or non-linear oligo-(alkylene glycol) side chains having variable chain length. The alkylene glycol may be selected from the group consisting of ethylene-, propylene-, butylene- or pentylene glycol. Preferably, the isocyanopeptides are functionalized with at least three ethylene glycol side chains. The peptides may comprise L-amino acids, D-amino acids or D, L-amino acids. The obtained oligoalkylene-functionalized polyisocyanopeptides are a new class of materials with unique thermo-responsive properties.

Abstract translation: 本发明涉及制备低聚（亚烷基二醇）官能化多异氰酸肽的方法，其包括以低聚（亚烷基二醇）侧链官能化异氰尿酸并随后聚合低聚 - 亚烷基二醇官能化的异氰尿苷的步骤。 可以用具有可变链长度的各种线性或非线性寡（亚烷基二醇）侧链来官能化几种异氰酸酯。 亚烷基二醇可以选自乙烯 - ，丙烯 - ，丁烯 - 或戊二醇。 优选地，异氰酸肽用至少三个乙二醇侧链进行官能化。 肽可以包含L-氨基酸，D-氨基酸或D，L-氨基酸。 获得的低聚亚烷基官能化多异氰酸肽是具有独特热响应特性的新一类材料。

公开(公告)号：US20220198651A1

公开(公告)日：2022-06-23

申请号：US17128430

申请日：2020-12-21

Applicant: Radboud University Nijmegen ,  CANON MEDICAL SYSTEMS CORPORATION

Inventor： Mathias PROKOP ,  Brian MOHR ,  Paul THOMSON ,  Ewan HEMINGWAY

IPC: G06T7/00

Abstract: An apparatus including processing circuitry configured to: acquire a plurality of sets of medical imaging data of a region of a subject, each set of data corresponding to a respective different measurement period; apply a filter to the plurality of medical imaging data sets to produce a plurality of filtered medical imaging data sets corresponding to the different measurement periods, wherein the applying of the filter is such that, for each of the medical imaging data sets, the filtering uses at least some information from the other medical imaging data sets acquired at the different time periods and wherein the applying of the filter comprises applying at least one constraint or condition and the constraint or condition comprises preserving at least one measure of intensity for each medical imaging data set.